申请人:Regenacy Pharmaceuticals, LLC
公开号:US10239837B2
公开(公告)日:2019-03-26
Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
本文提供了化合物、包含此类化合物的药物组合物以及使用此类化合物治疗与 HDAC1 和/或 HDAC2 活性相关的疾病或紊乱的方法。